Nate Diehl Awarded at Postdoc Day

Der Lab member, Nate Diehl, recently attended the 45th Annual Postdoc Faculty Research Day-- a symposium run primarily by the ITCMS Postdoc trainees and welcome to all of UNC Lineberger trainees and graduate students. Nate was awarded for Best Graduate Student Poster. He presented on Life without KRAS: profiling the KRAS-dependent kinome to identify novel therapeutic vulnerabilities … Continue reading Nate Diehl Awarded at Postdoc Day

Der Lab Publishes in Cancer Discovery

UNC Lineberger’s Channing Der, PhD, and Antje Schaefer, PhD. UNC UNC Lineberger's Channing Der, Ph.D. Sarah Graham Kenan Distinguished Professor in the UNC School of Medicine Department of Pharmacology was the co-corresponding author of a paper published in Cancer Discovery. Antje Schaefer, Ph.D., research assistant professor in the UNC School of Medicine Department of Pharmacology, … Continue reading Der Lab Publishes in Cancer Discovery

Der Lab Goes Purple for Pancreatic Awareness

For the month of November, the Der and Cox labs have gone purely purple. The dress code is inspired by the official pancreatic cancer ribbon and is worn all month to bring awareness to pancreatic cancer. See ABC 11's interview with Dr. Jen Jen Yeh and Dr. Kirsten Bryant here. Photos courtesy of the UNC … Continue reading Der Lab Goes Purple for Pancreatic Awareness

Researchers find KRAS gene mutation differences have implications for pancreatic cancer treatment

A new study from University of North Carolina Lineberger Comprehensive Cancer Center researchers reveals important findings about how a common genetic mutation in pancreatic cancer works to drive tumor growth. In the journal Cancer Discovery, researchers led by UNC Lineberger’s Channing Der, PhD, and Aaron Hobbs, PhD, reported details of the role of a particular mutation … Continue reading Researchers find KRAS gene mutation differences have implications for pancreatic cancer treatment

Channing Der Quoted by Bloomberg

Right DirectionThe findings follow data this summer that showed half of those treated with Amgen’s drug at a wide range of doses responded. The latest results more than doubled the number of patients treated with the highest dose and tracked them for three more months. It’s too early to know how long the benefits will last and … Continue reading Channing Der Quoted by Bloomberg

Der Lab Blue Ribbon Tour 2019

  August 5, 2019 Today, the Der and Cox labs were visited by the Blue Ribbon group of Wilmington, NC. The Blue Ribbon Run raises money for the Julie M. Brown and Christina M. Gianoplus Fund for Colon Cancer Research from Wilmington, NC. Members of the group included Ana Boudreau, event founder, and Sarah Powell, a … Continue reading Der Lab Blue Ribbon Tour 2019

Congratulations, Nate Diehl and Jenny Klomp!

Nate Diehl was awarded an NCI F30 Individual Predoctoral MD/Ph.D. fellowship entitled “Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer”. Jenny Klomp, Ph.D., was awarded an NCI F32 Individual Postdoctoral fellowship entitled “Defining the roles of the ERK MAPK in driving KRAS-mutant pancreatic cancer growth”. Congratulations to you both!

Dr. Kirsten Bryant’s recent publication in Nature Medicine stimulates excitement for a new therapeutic strategy for pancreatic cancer.

Published March 4th, 2019 in Nature Medicine, two new studies describe a combination approach to target the KRAS signaling pathway and a process called autophagy as a way to treat pancreatic cancer patients. Sources: Two Studies Point to New Combination Treatment for Pancreatic Cancer – Pancreatic Cancer Action Network, 3/4/2019 Advancements in Promising New Pancreatic … Continue reading Dr. Kirsten Bryant’s recent publication in Nature Medicine stimulates excitement for a new therapeutic strategy for pancreatic cancer.

channing der, lineberger

UNC Lineberger Writes: Researchers identify resistance mechanism to possible pancreatic cancer treatment

In the journal Cancer Cell, UNC Lineberger's Channing Der, PhD, and colleagues described how pancreatic cancer may develop resistance to ERK inhibitors in pancreatic cancer. November 16, 2018 Despite decades of research, treatments that can target a common mutation in the most frequently diagnosed type of pancreatic cancer have remained elusive. Now, University of North … Continue reading UNC Lineberger Writes: Researchers identify resistance mechanism to possible pancreatic cancer treatment